Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T51191 | ||||
Target Name | Histone deacetylase 2 (HDAC2) | ||||
Type of Target |
Clinical trial |
||||
Drug Potency against Target | Romidepsin | Drug Info | IC50 = 47 nM | [7] | |
(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one | Drug Info | IC50 = 990 nM | [6] | ||
1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one | Drug Info | IC50 = 3400 nM | [3] | ||
1,1,1-Trifluoro-8-phenoxy-octan-2-one | Drug Info | IC50 = 8000 nM | [3] | ||
2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide | Drug Info | IC50 = 500 nM | [15] | ||
2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide | Drug Info | IC50 = 500 nM | [15] | ||
2-(methylsulfonylthio)ethyl 2-propylpentanoate | Drug Info | IC50 = 9600 nM | [17] | ||
4-Benzoylamino-N-hydroxy-benzamide | Drug Info | IC50 = 210 nM | [13] | ||
4-Butyrylamino-N-hydroxy-benzamide | Drug Info | IC50 = 1500 nM | [8] | ||
4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide | Drug Info | IC50 = 369 nM | [7] | ||
4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide | Drug Info | IC50 = 610 nM | [11] | ||
4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide | Drug Info | IC50 = 149 nM | [1] | ||
4-Phenylbutyrohydroxamic acid | Drug Info | Ki = 430 nM | [22] | ||
5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide | Drug Info | IC50 = 2580 nM | [9] | ||
5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione | Drug Info | IC50 = 450 nM | [17] | ||
5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide | Drug Info | IC50 = 720 nM | [19] | ||
5-Mercapto-pentanoic acid phenylamide | Drug Info | IC50 = 6200 nM | [11] | ||
6-benzenesulfinylhexanoic acid hydroxamide | Drug Info | IC50 = 60 nM | [14] | ||
6-benzenesulfonylhexanoic acid hydroxamide | Drug Info | IC50 = 40 nM | [14] | ||
6-Mercapto-hexanoic acid phenylamide | Drug Info | IC50 = 370 nM | [11] | ||
6-Phenoxy-hexane-1-thiol | Drug Info | IC50 = 11000 nM | [11] | ||
6-phenylsulfanylhexanoic acid hydroxamide | Drug Info | IC50 = 120 nM | [14] | ||
7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | IC50 = 620 nM | [6] | ||
7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one | Drug Info | IC50 = 2600 nM | [3] | ||
7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | IC50 = 1100 nM | [6] | ||
7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | IC50 = 520 nM | [6] | ||
7-Biphenyl-4-yl-heptanoic acid hydroxyamide | Drug Info | IC50 = 58 nM | [5] | ||
7-Mercapto-heptanoic acid benzothiazol-2-ylamide | Drug Info | IC50 = 340 nM | [11] | ||
7-Mercapto-heptanoic acid biphenyl-3-ylamide | Drug Info | IC50 = 75 nM | [11] | ||
7-Mercapto-heptanoic acid biphenyl-4-ylamide | Drug Info | IC50 = 1100 nM | [11] | ||
7-Mercapto-heptanoic acid pyridin-3-ylamide | Drug Info | IC50 = 110 nM | [11] | ||
7-Mercapto-heptanoic acid quinolin-3-ylamide | Drug Info | IC50 = 72 nM | [11] | ||
7-Phenoxy-heptanoic acid hydroxyamide | Drug Info | IC50 = 330 nM | [5] | ||
8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one | Drug Info | IC50 = 2800 nM | [3] | ||
8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one | Drug Info | IC50 = 2900 nM | [3] | ||
8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid | Drug Info | IC50 = 3.7 nM | [4] | ||
8-Mercapto-octanoic acid phenylamide | Drug Info | IC50 = 1500 nM | [11] | ||
8-Oxo-8-phenyl-octanoic acid | Drug Info | IC50 = 270 nM | [1] | ||
8-Phenyl-octanoic acid hydroxyamide | Drug Info | IC50 = 560 nM | [5] | ||
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide | Drug Info | IC50 = 6700 nM | [3] | ||
Cyclostellettamine derivative | Drug Info | IC50 = 17000 nM | [10] | ||
N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide | Drug Info | IC50 = 10000 nM | [23] | ||
N-(2-amino-5-(furan-2-yl)phenyl)benzamide | Drug Info | IC50 = 1800 nM | [23] | ||
N-(2-amino-5-(furan-3-yl)phenyl)benzamide | Drug Info | IC50 = 810 nM | [23] | ||
N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide | Drug Info | IC50 = 3900 nM | [23] | ||
N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide | Drug Info | IC50 = 5800 nM | [23] | ||
N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide | Drug Info | IC50 = 390 nM | [18] | ||
N-(2-aminophenyl)-4-methoxybenzamide | Drug Info | IC50 = 900 nM | [16] | ||
N-(2-aminophenyl)benzamide | Drug Info | IC50 = 10000 nM | [23] | ||
N-(2-aminophenyl)nicotinamide | Drug Info | IC50 = 6980 nM | [18] | ||
N-(2-aminophenyl)quinoxaline-6-carboxamide | Drug Info | IC50 = 2000 nM | [16] | ||
N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide | Drug Info | IC50 = 2800 nM | [12] | ||
N-(2-Mercapto-ethyl)-N'-phenyl-succinamide | Drug Info | IC50 = 12500 nM | [12] | ||
N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide | Drug Info | IC50 = 13000 nM | [23] | ||
N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide | Drug Info | IC50 = 5000 nM | [23] | ||
N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide | Drug Info | IC50 = 3400 nM | [23] | ||
N-(4-amino-3'-methylbiphenyl-3-yl)benzamide | Drug Info | IC50 = 7200 nM | [23] | ||
N-(4-amino-4'-bromobiphenyl-3-yl)benzamide | Drug Info | IC50 = 600 nM | [23] | ||
N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide | Drug Info | IC50 = 1400 nM | [23] | ||
N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide | Drug Info | IC50 = 860 nM | [23] | ||
N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide | Drug Info | IC50 = 5000 nM | [23] | ||
N-(4-aminobiphenyl-3-yl)benzamide | Drug Info | IC50 = 900 nM | [23] | ||
N-(4-aminobiphenyl-3-yl)nicotinamide | Drug Info | IC50 = 900 nM | [18] | ||
N-(4-hydroxybiphenyl-3-yl)benzamide | Drug Info | IC50 = 200 nM | [18] | ||
N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide | Drug Info | IC50 = 1566 nM | [7] | ||
N-(6-Hydroxycarbamoyl-hexyl)-benzamide | Drug Info | IC50 = 568 nM | [1] | ||
N-(6-Mercapto-hexyl)-benzamide | Drug Info | IC50 = 360 nM | [11] | ||
N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide | Drug Info | IC50 = 68 nM | [13] | ||
N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide | Drug Info | IC50 = 34 nM | [13] | ||
N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide | Drug Info | IC50 = 54 nM | [13] | ||
N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide | Drug Info | IC50 = 1100 nM | [21] | ||
N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide | Drug Info | IC50 = 44 nM | [13] | ||
N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide | Drug Info | IC50 = 250 nM | [13] | ||
N-Hydroxy-4-(pentanoylamino-methyl)-benzamide | Drug Info | IC50 = 3600 nM | [8] | ||
N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide | Drug Info | IC50 = 2500 nM | [8] | ||
N-Hydroxy-4-phenylacetylamino-benzamide | Drug Info | IC50 = 157 nM | [13] | ||
N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide | Drug Info | IC50 = 1860 nM | [19] | ||
N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide | Drug Info | IC50 = 330 nM | [19] | ||
N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide | Drug Info | IC50 = 820 nM | [19] | ||
N7-hydroxy-2-methoxy-N1-phenylheptanediamide | Drug Info | IC50 = 500 nM | [15] | ||
N7-hydroxy-N1-phenyl-2-propoxyheptanediamide | Drug Info | IC50 = 500 nM | [15] | ||
N8,2-dihydroxy-N1-phenyloctanediamide | Drug Info | IC50 = 500 nM | [15] | ||
N8-hydroxy-2-methoxy-N1-phenyloctanediamide | Drug Info | IC50 = 500 nM | [15] | ||
Octanedioic acid bis-hydroxyamide | Drug Info | IC50 = 1150 nM | [2] | ||
Octanedioic acid hydroxyamide pyridin-2-ylamide | Drug Info | IC50 = 248 nM | [1] | ||
Octanedioic acid hydroxyamide pyridin-4-ylamide | Drug Info | IC50 = 306 nM | [1] | ||
PSAMMAPLIN A | Drug Info | IC50 = 4 nM | [7] | ||
ST-2986 | Drug Info | IC50 = 11000 nM | [20] | ||
ST-2987 | Drug Info | IC50 = 2670 nM | [20] | ||
Tacedinaline | Drug Info | Ki = 190 nM | [22] | ||
References | |||||
REF 1 | Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. | ||||
REF 2 | Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309. | ||||
REF 3 | Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. | ||||
REF 4 | Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5. | ||||
REF 5 | A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. | ||||
REF 6 | Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. | ||||
REF 7 | Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. | ||||
REF 8 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. | ||||
REF 9 | Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. | ||||
REF 10 | Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. | ||||
REF 11 | Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. | ||||
REF 12 | Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. | ||||
REF 13 | Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. | ||||
REF 14 | Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. | ||||
REF 15 | Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. | ||||
REF 16 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. | ||||
REF 17 | New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. | ||||
REF 18 | Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). | ||||
REF 19 | Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12. | ||||
REF 20 | N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. | ||||
REF 21 | Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetyla... Eur J Med Chem. 2009 Nov;44(11):4470-6. | ||||
REF 22 | Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. | ||||
REF 23 | Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.